In Brief: Barton hearing
This article was originally published in The Tan Sheet
Executive Summary
Barton hearing: House Commerce/oversight subcommittee to hear testimony from patients of Stanislaw Burzynski, MD, at a Feb. 29 hearing on cancer patients' access to experimental drugs. Burzynski, who has been conducting clinical trials of an unconventional "anti-neoplaston" cancer therapy in 300 terminal patients, is under federal grand jury indictment for 75 counts of FDA violations, mail fraud and contempt ("The Tan Sheet" Nov. 27, 1995, p. 12). According to a Commerce document, the patients currently await the decision of a Texas federal court judge regarding the future of the Burzynski Institute, and in turn, their ability to continue with the controversial treatment. Subcommittee Chairman Joe Barton (R-Tex.) has held up Burzynski as a "victim" of the legal system ("The Tan Sept. 18, 1995, p. 8), suggesting the need for FDA reform ("The Tan Nov. 20, 1995, p. 20)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning